JOURNAL BROWSE
Search
Advanced SearchSearch Tips
In Search for a Common Pathway for Health Issues in Men - the Sign of a Holmesian Deduction
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
In Search for a Common Pathway for Health Issues in Men - the Sign of a Holmesian Deduction
Aoun, Fouad; Chemaly, Anthony Kallas; Albisinni, Simone; Zanaty, Marc; Roumeguere, Thierry;
  PDF(new window)
 Abstract
The evidence for the existence of a common pathway for health issues in men is presented in this review. Several epidemiological studies have shown that conditions like cardiovascular diseases (CVD), metabolic syndrome, diabetes, lower urinary tract symptom (LUTS), erectile dysfunction (ED), prostate cancer, hypogonadism, depression and suicide can be associated as risk factors for each other. Thus, the risk of CVD is significantly increased in men with metabolic syndrome, ED, hypogonadism, prostate cancer and/or LUTS. In addition, the above mentioned conditions are more prevalent in atherosclerotic patients. In addition, growing evidence indicates that low androgen levels can cause metabolic syndrome. In addition, obesity, dyslipidaemia and diabetes can further reduce androgen levels potentiating their adverse effect. Low testosterone levels are also associated with a higher incidence of aggressive prostate cancer on biopsy and on definitive pathology, and lower probability of abiraterone response in the metastatic setting. Several recent studies point towards diffuse endothelial dysfunction and dysregulated pro-inflammatory state as the biological link between all these disorders. Our current hypothesis is that oxidative stress caused by these dysfunctions explains the pathogenesis of each of these conditions.
 Keywords
Epidemiology;men`s health;atherosclerosis;erectile dysfunction;LUTS/BPH;hypogonadism;prostate;
 Language
English
 Cited by
1.
Relationship between oxidative stress and erectile function, Free Radical Research, 2017, 51, 11-12, 924  crossref(new windwow)
 References
1.
Al Hayek AA, Khader YS, Jafal S, et al (2013). Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J Family Community Med, 20, 179-86. crossref(new window)

2.
Albertsen PC, Klotz L, Tombal B, et al (2014). Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol, 65, 565-73. crossref(new window)

3.
Alkamel A, Shafiee A, Jalali A, et al (2014). The association between premature coronary artery disease and level of testosterone in young adult males. Arch Iran Med, 17, 545-50.

4.
Anitha B, Inamadar AC, Ragunatha S (2009). Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg, 2, 12-6. crossref(new window)

5.
Araujo AB, Dixon JM, Suarez EA, et al (2011). Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab, 96, 3007-19. crossref(new window)

6.
Arrabal-Polo MA, Vera-Arroyo B, Lahoz-Garcia C, et al (2014). Erectile dysfunction, metabolic syndrome and arterial disease. Clinical-pathological relation by carotid ultrasonography. Actas Urol Esp, 38, 179-83.

7.
Azadzoi KM, Radisavljevic ZM, Siroky MB (2008). Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder. Urol, 71, 979-83. crossref(new window)

8.
Bansal D, Bhansali A, Kapil G, et al (2013). Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis, 16, 151-8.

9.
Barqawi A, Crawford ED (2006). Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int J Impot Res, 18, 323-8. crossref(new window)

10.
Bassil N, Alkaade S, Morley JE (2009). The benefits and risks of testosterone replacement therapy: a review. Prostate Cancer Prostatic Dis, 5, 427-48.

11.
Beatrice AM, Dutta D, Kumar M, et al (2014). Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes Metab Syndr Obes, 7, 481-6.

12.
Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, et al (2009). Racial differences in risk of prostate cancer associated with metabolic syndrome. Urol, 74, 185-90. crossref(new window)

13.
Berger AP, Bartsch G, Deibl M, et al (2006). Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int, 98, 1038-42. crossref(new window)

14.
Berger AP, Kofler K, Bektic J, et al (2003). Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate, 57, 57-65. crossref(new window)

15.
Blumentals WA, Gomez-Caminero A, Joo S, et al (2004). Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res, 16, 350-3. crossref(new window)

16.
Borst SE, Mulligan T (2007). Testosterone replacement therapy for older men. Clin Interv Aging, 2, 561-6.

17.
Botto H, Neuzillet Y, Lebret T, et al (2011). High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol, 186, 1400-5. crossref(new window)

18.
Bouwman, II, Blanker MH, Schouten BW, et al (2015). Are lower urinary tract symptoms associated with cardiovascular disease in the Dutch general population? Results from the Krimpen study. World J Urol, 33, 669-76. crossref(new window)

19.
Bouwman, II, Van Der Heide WK, Van Der Meer K, et al (2009). Correlations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: are there differences between male populations from primary healthcare and Urol clinics? A review of the current knowledge. Eur J Gen Pract, 15, 128-35. crossref(new window)

20.
Boyle P, Robertson C, Mazzetta C, et al (2003). The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int, 92, 719-25. crossref(new window)

21.
Braun M, Wassmer G, Klotz T, et al (2000). Epidemiology of erectile dysfunction: results of the 'cologne male survey'. Int J Impot Res, 12, 305-11. crossref(new window)

22.
Cai X, Tian Y, Wu T, et al (2014). Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and metaanalysis of randomized controlled trials. Asian J Androl, 16, 146-52. crossref(new window)

23.
Camacho EM, Huhtaniemi IT, O'Neill TW, et al (2013). Ageassociated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European male ageing study. Eur J Endocrinol, 168, 445-55. crossref(new window)

24.
Caminiti G, Volterrani M, Iellamo F, et al (2009). Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol, 54, 919-27. crossref(new window)

25.
Chang IH, Oh SY, Kim SC (2009). A possible relationship between testosterone and lower urinary tract symptoms in men. J Urol, 182, 215-20. crossref(new window)

26.
Colombo MG, Meisinger C, Amann U, et al (2015). Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry. Cardiovasc Diabetol, 14, 24. crossref(new window)

27.
Corona G, Lee DM, Forti G, et al (2010). Age-related changes in general and sexual health in middle-aged and older men: results from the European male ageing study (EMAS). J Sex Med, 7, 1362-80. crossref(new window)

28.
Corona G, Mannucci E, Schulman C, et al (2006). Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol, 50, 595-604. crossref(new window)

29.
Corona G, Rastrelli G, Monami M, et al (2011). Hypogonadism as a risk factor for cardiovascular mortality in men: a metaanalytic study. Eur J Endocrinol, 165, 687-701. crossref(new window)

30.
Couillard C, Gagnon J, Bergeron J, et al (2000). Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab, 85, 1026-31.

31.
Cutini PH, Campelo AE, Agriello E, et al (2012). The role of sex steroids on cellular events involved in vascular disease. J Steroid Biochem Mol Biol, 132, 322-30. crossref(new window)

32.
Dal Pra A, Cury FL, Souhami L (2010). Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol, 17, 28-38.

33.
Dandona P, Dhindsa S (2011). Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab, 96, 2643-51. crossref(new window)

34.
Davies JD, Carpenter KL, Challis IR, et al (2005). Adipocytic differentiation and liver x receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. J Biol Chem, 280, 3911-9. crossref(new window)

35.
De Nunzio C, Aronson W, Freedland SJ, et al (2012). The correlation between metabolic syndrome and prostatic diseases. Eur Urol, 61, 560-70. crossref(new window)

36.
Dean RC, Lue TF (2005). Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am, 32, 379-95. crossref(new window)

37.
English KM, Mandour O, Steeds RP, et al (2000a). Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 21, 890-4. crossref(new window)

38.
English KM, Steeds RP, Jones TH, et al (2000b). Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, doubleblind, placebo-controlled study. Circulat, 102, 1906-11. crossref(new window)

39.
Esposito K, Giugliano F, Martedi E, et al (2005). High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care, 28, 1201-3. crossref(new window)

40.
Filgueira FP, Lobato NS, DosSantos RA, et al (2012). Endogenous testosterone increases leukocyte-endothelial cell interaction in spontaneously hypertensive rats. Life Sci, 90, 689-94. crossref(new window)

41.
Finkle WD, Greenland S, Ridgeway GK, et al (2014). Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 9, 85805. crossref(new window)

42.
Fisher WA, Rosen RC, Eardley I, et al (2005). Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med, 2, 675-84. crossref(new window)

43.
Foradori CD, Weiser MJ, Handa RJ (2008). Non-genomic actions of androgens. Front Neuroendocrinol, 29, 169-81. crossref(new window)

44.
Frattaroli J, Weidner G, Dnistrian AM, et al (2008). Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urol, 72, 1319-23. crossref(new window)

45.
Fukui M, Kitagawa Y, Nakamura N, et al (2003). Association between elevated testosterone and development of microalbuminuria during puberty in female subjects with type 1 diabetes: response to Amin et Al. Diabetes Care, 26, 2966-7.

46.
Gacci M, Eardley I, Giuliano F, et al (2011). Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 60, 809-25. crossref(new window)

47.
Gandaglia G, Briganti A, Jackson G, et al (2014). A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol, 65, 968-78. crossref(new window)

48.
Garcia-Cruz E, Leibar-Tamayo A, Romero-Otero J, et al (2014). Marked testosterone deficiency-related symptoms may be associated to higher metabolic risk in men with low testosterone levels. J Sex Med, 11, 2292-301. crossref(new window)

49.
Garcia-Cruz E, Leibar-Tamayo A, Romero J, et al (2013). Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med, 10, 2529-38. crossref(new window)

50.
Ghafar MA, Puchner PJ, Anastasiadis AG, et al (2002). Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep, 3, 292-6. crossref(new window)

51.
Giovambattista A, Suescun MO, Nessralla CC, et al (2003). Modulatory effects of leptin on leydig cell function of normal and hyperleptinemic rats. Neuroendocrinol, 78, 270-9. crossref(new window)

52.
Gurbuz C, Canat L, Atis G, et al (2012). The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. Kaohsiung J Med Sci, 28, 649-53. crossref(new window)

53.
Haider A, Gooren LJ, Padungtod P, et al (2009). Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia, 41, 7-13. crossref(new window)

54.
Haider A, Gooren LJ, Padungtod P, et al (2010). Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes, 118, 167-71. crossref(new window)

55.
Hammarsten J, Hogstedt B, Holthuis N, et al (1998). Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 1, 157-62. crossref(new window)

56.
Haring R, Baumeister SE, Volzke H, et al (2011). Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil, 18, 86-96.

57.
Haring R, Volzke H, Steveling A, et al (2010). Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J, 31, 1494-501. crossref(new window)

58.
Ho T, Howard LE, Vidal AC, et al (2014). Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. Clin Cancer Res, 20, 5331-8. crossref(new window)

59.
Holmang S, Marin P, Lindstedt G, et al (1993). Effect of longterm oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate, 23, 99-106. crossref(new window)

60.
Huncharek M, Haddock KS, Reid R, et al (2010). Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health, 100, 693-701. crossref(new window)

61.
Hyde Z, Norman PE, Flicker L, et al (2012). Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab, 97, 179-89. crossref(new window)

62.
Isidori AM, Buvat J, Corona G, et al (2014). A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol, 65, 99-112. crossref(new window)

63.
Isidori AM, Giannetta E, Gianfrilli D, et al (2005). Effects of testosterone on sexual function in men: results of a metaanalysis. Clin Endocrinol, 63, 381-94. crossref(new window)

64.
Jackson G, Boon N, Eardley I, et al (2010). Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract, 64, 848-57. crossref(new window)

65.
Kalra S, Agrawal N, Kumar S, et al (2010). Testosterone replacement in male hypogonadism. Clin Pharmacol, 2, 149-53.

66.
Kapoor D, Aldred H, Clark S, et al (2007). Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care, 30, 911-7. crossref(new window)

67.
Kapoor D, Goodwin E, Channer KS, et al (2006). Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol, 154, 899-906. crossref(new window)

68.
Kapoor D, Malkin CJ, Channer KS, et al (2005). Androgens, insulin resistance and vascular disease in men. Clin Endocrinol, 63, 239-50. crossref(new window)

69.
Karazindiyanoglu S, Cayan S (2008). The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male, 11, 146-9. crossref(new window)

70.
Keating NL, O'Malley AJ, Smith MR (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol, 24, 4448-56. crossref(new window)

71.
Kenny AM, Kleppinger A, Annis K, et al (2010). Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc, 58, 1134-43. crossref(new window)

72.
Ketchandji M, Kuo YF, Shahinian VB, et al (2009). Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc, 57, 24-30. crossref(new window)

73.
Khandrika L, Kumar B, Koul S, et al (2009). Oxidative stress in prostate cancer. Cancer Lett, 282, 125-36. crossref(new window)

74.
Khaw KT, Dowsett M, Folkerd E, et al (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulat, 116, 2694-701. crossref(new window)

75.
Khera M, Crawford D, Morales A, et al (2014). A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol, 65, 115-23. crossref(new window)

76.
Kim S, Jeong JY, Choi YJ, et al (2010). Association between lower urinary tract symptoms and vascular risk factors in aging men: the hallym aging Study. Korean J Urol, 51, 477-82. crossref(new window)

77.
Kirby M, Chapple C, Jackson G, et al (2013). Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract, 67, 606-18. crossref(new window)

78.
Ko YH, Moon du G, Moon KH (2013). Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J Mens Health, 31, 47-52. crossref(new window)

79.
Koritsiadis G, Tyritzis SI, Koutalellis G, et al (2010). The effect of alpha-blocker treatment on bladder hypoxia inducible factor-1 alpha regulation during lower urinary tract obstruction. Int Braz J Urol, 36, 86-94. crossref(new window)

80.
Kumar P, Kumar N, Thakur DS, et al (2010). Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res, 1, 297-301. crossref(new window)

81.
Kupelian V, Araujo AB, Chiu GR, et al (2010). Relative contributions of modifiable risk factors to erectile dysfunction: results from the boston area community health (BACH) survey. Prev Med, 50, 19-25. crossref(new window)

82.
Laukkanen JA, Laaksonen DE, Niskanen L, et al (2004). Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev, 13, 1646-50.

83.
Lee RK, Chung D, Chughtai B, et al (2012). Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int, 110, 540-5. crossref(new window)

84.
Lee SH, Park TJ, Bae MH, et al (2013). Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol, 54, 750-5. crossref(new window)

85.
Levin RM, O'Connor LJ, Leggett RE, et al (2003). Focal hypoxia of the obstructed rabbit bladder wall correlates with intermediate decompensation. Neurourol Urodyn, 22, 156-63. crossref(new window)

86.
Lin HJ, Weng SF, Yang CM, et al (2013). Risk of hospitalization for acute cardiovascular events among subjects with lower urinary tract symptoms: a nationwide population-based study. PLoS One, 8, 66661. crossref(new window)

87.
Liu Y, Hu F, Li D, et al (2011). Does physical activity reduce the risk of prostate cancer? A systematic review and metaanalysis. Eur Urol, 60, 1029-44. crossref(new window)

88.
Lu YL, Kuang L, Zhu H, et al (2007). Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alphareductase inhibitor. Asian J Androl, 9, 843-7. crossref(new window)

89.
Lund Haheim L, Wisloff TF, Holme I, et al (2006). Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol, 164, 769-74. crossref(new window)

90.
Malkin CJ, Pugh PJ, Morris PD, et al (2010). Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 96, 1821-5. crossref(new window)

91.
Margel D, Urbach D, Lipscombe LL, et al (2013). Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst, 105, 1123-31. crossref(new window)

92.
Mayi TH, Daoudi M, Derudas B, et al (2012). Human adipose tissue macrophages display activation of cancer-related pathways. J Biol Chem, 287, 21904-13. crossref(new window)

93.
McEvoy JW, Nasir K, DeFilippis AP, et al (2015). Relationship of cigarette smoking with inflammation and subclinical vascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol, 35, 1002-10. crossref(new window)

94.
McVary KT (2005). Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol, 47, 838-45. crossref(new window)

95.
Mirone V, Imbimbo C, Fusco F, et al (2009). Androgens and morphologic remodeling at penile and cardiovascular levels: a common piece in complicated puzzles? Eur Urol, 56, 309-16. crossref(new window)

96.
Mondul AM, Clipp SL, Helzlsouer KJ, et al (2010). Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control, 21, 61-8. crossref(new window)

97.
Montorsi P, Ravagnani PM, Galli S, et al (2006a). Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J, 27, 2632-9. crossref(new window)

98.
Montorsi P, Ravagnani PM, Galli S, et al (2006b). Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol, 50, 721-31. crossref(new window)

99.
Morgans AK, Fan KH, Koyama T, et al (2015). Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol, 193, 1226-31. crossref(new window)